240.08 USD
↗ 4.07 (1.73%)AT CLOSE (11:59 AM EDT)
Alnylam Pharmaceuticals, Inc.
ALNYNASDAQ • USD
239.26
↘ 0.82 (0.34%)
POST MARKET (AS OF 07:38 PM EDT)
Post Market
AS OF 07:38 PM EDT
239.26
↘ 0.82 (0.34%)
Market: OPEN
Alnylam Pharmaceuticals, Inc. (ALNY) trades at $239.26 per share. There is a divergence between signals — underlying fundamentals rate "Buy" but technical indicators lean "Sell". This is driven by a robust Altman Z-Score, exceptional Return on Equity (59.7%) and a bearish Death Cross on the long-term moving averages. On the valuation front, ALNY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 25, 2026.
Open?$236.56
High?$240.67
Low?$235.41
Prev. Close?$236.01
Volume?1.6M
Avg. Volume?2.0M
VWAP?$238.74
Rel. Volume?0.78x
Bid / Ask
Bid?$228.25 × 40
Ask?$248.22 × 40
Spread?$19.97
Midpoint?$238.24
Valuation & Ratios
Market Cap?31.6B
Shares Out?133.8M
Float?133.3M
Float %?99.9%
P/E Ratio?39.09
P/B Ratio?23.32
EPS?$6.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Themes
Employees
2.5K
Market Cap
31.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2004-05-28
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?98
Momentum?62
Short Sent.?75
Piotroski F-Score?5/9Mixed
Altman Z-Score?5.04Safe
Confidence?74%Moderate
Short InterestLow
Short % of Float?3.58%Low
Short Interest?4.8M
Days to Cover?2.4
Free Float133.3M
Avg Daily Volume2.0M
Settlement Date2026-08-14
Financial Health
Current Ratio?3.05Strong
Quick Ratio?2.99Strong
Cash Ratio?1.13Strong
Debt/Equity?0.75Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score39/100
P/E?39.1PRICEY▾
Peers100
S&P18
P/B?23.32HIGH▾
Peers100
S&P3
P/S?6.57FAIR▾
Peers100
S&P19
P/FCF?39.8PRICEY▾
Peers100
S&P17
EV/EBITDA?29.3HIGH▾
Peers100
S&P10
EV/Sales?6.43HIGH▾
Peers100
S&P24
Returns & Efficiency
ROE?59.7%STRONG▾
Peers50
S&P93
ROA?14.5%STRONG▾
Peers50
S&P86
Cash Flow & Enterprise
FCF?$793.9M
Enterprise Value?$30.9B
Fundamentals ratios updated end of day